<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622073</url>
  </required_header>
  <id_info>
    <org_study_id>REC REF 2017-016</org_study_id>
    <nct_id>NCT03622073</nct_id>
  </id_info>
  <brief_title>Misoprostol Treatment of Mid Trimester Incomplete Abortion by Midwives and Doctors in Uganda.</brief_title>
  <official_title>Safety, Effectiveness and Acceptability of Misoprostol When Administered by Midwives Versus Physicians for Management of Incomplete Mid Trimester Abortion in Uganda: a Randomized Controlled Equivalence Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is estimated that 47,000 women die every year due to consequences of unsafe abortion
      globally. The majority of pregnancy related deaths occur in low income countries where
      induced abortion is restricted, unmet need for contraception is high, and women's status is
      low. Uganda has a high total fertility rate of 5.4 children per woman, low contraceptive
      prevalence rate of 39%, and more than half of these pregnancies are unintended. Induced
      abortion is controversial and restricted in Uganda and legally permitted only to save a
      woman's life. As a result, women often resort to unsafe abortion- that's either performed by
      a person lacking the necessary skills or in an environment that does not conform to minimal
      medical standards. Of the estimated 314,304 women who undergo unsafe abortions each year in
      Uganda, about 41% receive treatment for complications. This equates to an annual rate of 12
      per 1,000 women aged 15-49 years being hospitalized for induced abortion complications, which
      is considered high in international comparison. In Uganda, outside the larger hospitals and
      private settings, access to safe post abortion care and surgical facilities are scarce.
      Studies have showed that trained midwives can deliver safe, effective and acceptable post
      abortion care using misoprostol in the first trimester. Currently in Uganda, treatment of
      second trimester incomplete abortion is restricted to physicians. This study will provide
      evidence on whether treatment for incomplete abortion using misoprostol by mid-level
      providers can be extended to the early second trimester period. The investigators hypothesize
      that misoprostol treatment for incomplete second trimester abortion provided by midwives is
      equivalent to that of physicians requiring no further surgical intervention. Women with
      incomplete abortion will be randomly allocated to undergo a clinical assessment and treatment
      with misoprostol either by physician or midwife with safety and effectiveness as main
      outcomes in the RCT carried out in hospital and high volume health centres in Central Uganda.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled equivalence trial (RCT) implemented at eight hospitals and Health
      centres in Central Uganda will include 1192 eligible women with incomplete abortion of
      uterine size &gt;12 weeks up to 18 weeks. Following informed consent, each participant will be
      randomly assigned to undergo a clinical assessment and treatment by either a midwife
      (intervention arm) or physician (control arm); receive 400mcg of misoprostol administered
      sublingually 3 hourly up to 5 doses within 24 hours at the health facility until a complete
      abortion is confirmed. Women who do not achieve a complete abortion within 24 hours will
      undergo a surgical method of uterine evacuation. Pre-discharge information on danger signs,
      contraceptive counselling and provision will be done with follow up 14 days later to assess
      secondary outcomes and acceptability. Analyses will be by Intention-to-Treat (ITT).
      Background characteristics and outcomes will be presented using descriptive statistics.
      Differences between groups will be analyzed using risk difference (95% CI) and equivalence
      established if it lies between the pre-defined range of -5% to +5%. Chi-square test will be
      used for comparison of outcome and t test used to compare mean values. P-values equal to or
      lower than 0.05 will be considered statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete abortion</measure>
    <time_frame>24 hours from treatment initiation</time_frame>
    <description>Number of participants who will have expelled all the products of conception as evidenced by cessation of abdominal cramps, vaginal bleeding and closed cervical os.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Excessive vaginal bleeding</measure>
    <time_frame>24 hours from treatment initiation</time_frame>
    <description>Participant reporting use of more than 3 pads in an hour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Pain</measure>
    <time_frame>24 hours from treatment initiation</time_frame>
    <description>Pain will be defined as discomfort experienced in the lower abdomen using a visual analogue scale with a minimum score of zero representing no pain and a maximum score of 10 representing most pain. A higher score represents a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unscheduled visits</measure>
    <time_frame>14-28 days post treatment</time_frame>
    <description>Participant presenting at the study site when not expected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Women's acceptability of the post abortion care provider</measure>
    <time_frame>14-28 days post treatment</time_frame>
    <description>Acceptability will be positive reporting of treatment experience, recommendation of method to a friend or reuse of same method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1192</enrollment>
  <condition>Incomplete Abortion</condition>
  <arm_group>
    <arm_group_label>Misoprostol treatment by Midwife</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of misoprostol by the midwife and assessment for the primary outcome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol treatment by Doctor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of misoprostol by the doctor and assessment for the primary outcome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Misoprostol treatment by Midwife</intervention_name>
    <description>Medical management of incomplete abortion</description>
    <arm_group_label>Misoprostol treatment by Midwife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Misoprostol treatment by Doctor</intervention_name>
    <description>Medical management of incomplete abortion</description>
    <arm_group_label>Misoprostol treatment by Doctor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vaginal bleeding

          -  With or without contractions with a uterine size &gt; 12 weeks to &lt; 18 weeks

          -  History of partial expulsion

          -  Open cervical os.

        Exclusion Criteria:

          -  Known allergy to misoprostol,

          -  Unstable hemodynamic status (systolic blood pressure &lt; 90mmHg) and shock

          -  Signs of pelvic infection and/or sepsis

          -  Previous caesarean delivery/uterine scar

          -  Suspected extra uterine pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina G Danielsson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josaphat Byamugisha, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Atuhairwe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Atuhairwe, MD</last_name>
    <phone>256705629530</phone>
    <email>atususan96@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Entebbe Hospital</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Atuhairwe, MD</last_name>
      <phone>256705629530</phone>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gombe Hospital</name>
      <address>
        <city>Gombe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Atuhairwe, MD</last_name>
      <phone>256705629530</phone>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kawempe Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan P Atuhairwe</last_name>
      <phone>256705629530</phone>
      <phone_ext>256705629530</phone_ext>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kayunga Hospital</name>
      <address>
        <city>Kayunga</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan P Atuhairwe</last_name>
      <phone>256705629530</phone>
      <phone_ext>256705629530</phone_ext>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kawolo Hospital</name>
      <address>
        <city>Lugazi</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan P Atuhairwe</last_name>
      <phone>256705629530</phone>
      <phone_ext>256705629530</phone_ext>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luwero HC IV</name>
      <address>
        <city>Luwero</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Atuhairwe, MD</last_name>
      <phone>256705629530</phone>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masaka Hospital</name>
      <address>
        <city>Masaka</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Atuhairwe, MD</last_name>
      <phone>256705629530</phone>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mityana Hospital</name>
      <address>
        <city>Mityana</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Atuhairwe, MD</last_name>
      <phone>256705629530</phone>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mpigi HC IV</name>
      <address>
        <city>Mpigi</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Atuhairwe, MD</last_name>
      <phone>256705629530</phone>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kiganda HC IV</name>
      <address>
        <city>Mubende</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan P Atuhairwe</last_name>
      <phone>256705629530</phone>
      <phone_ext>256705629530</phone_ext>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mukono HC IV</name>
      <address>
        <city>Mukono</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Atuhairwe, MD</last_name>
      <phone>256705629530</phone>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nakaseke Hospital</name>
      <address>
        <city>Nakaseke</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Atuhairwe, MD</last_name>
      <phone>256705629530</phone>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kasangati HC IV</name>
      <address>
        <city>Wakiso</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan P Atuhairwe</last_name>
      <phone>256705629530</phone>
      <phone_ext>256705629530</phone_ext>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wakiso HC IV</name>
      <address>
        <city>Wakiso</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan P Atuhairwe</last_name>
      <phone>256705629530</phone>
      <phone_ext>256705629530</phone_ext>
      <email>atususan96@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.who.int/reproductivehealth/publications/unsafe_abortion/9789241548434/en/</url>
    <description>World Health Organization Safe abortion technical and policy guidance for health systems.</description>
  </link>
  <reference>
    <citation>Faúndes A. Strategies for the prevention of unsafe abortion. Int J Gynaecol Obstet. 2012 Oct;119 Suppl 1:S68-71. Epub 2012 Aug 9.</citation>
    <PMID>22883917</PMID>
  </reference>
  <reference>
    <citation>Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B, Rossier C, Gerdts C, Tunçalp Ö, Johnson BR Jr, Johnston HB, Alkema L. Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. Lancet. 2016 Jul 16;388(10041):258-67. doi: 10.1016/S0140-6736(16)30380-4. Epub 2016 May 11.</citation>
    <PMID>27179755</PMID>
  </reference>
  <reference>
    <citation>Uganda Bureau of Statistcs (UBOS) and ICF. 2017. Uganda Demographic and Health Survey 2016: Key Indicators Report. Kampala, Uganda: UBOS, and Rockville, Maryland, USA: UBOS and ICF.</citation>
  </reference>
  <reference>
    <citation>Hussain R. Unintended pregnancy and abortion in Uganda. Issues Brief (Alan Guttmacher Inst). 2013 Jan;(2):1-8.</citation>
    <PMID>23550324</PMID>
  </reference>
  <reference>
    <citation>Prada E, Atuyambe LM, Blades NM, Bukenya JN, Orach CG, Bankole A. Incidence of Induced Abortion in Uganda, 2013: New Estimates Since 2003. PLoS One. 2016 Nov 1;11(11):e0165812. doi: 10.1371/journal.pone.0165812. eCollection 2016.</citation>
    <PMID>27802338</PMID>
  </reference>
  <reference>
    <citation>Mark AG, Edelman A, Borgatta L. Second-trimester postabortion care for ruptured membranes, fetal demise, and incomplete abortion. Int J Gynaecol Obstet. 2015 May;129(2):98-103. doi: 10.1016/j.ijgo.2014.11.011. Epub 2015 Jan 19. Review.</citation>
    <PMID>25660084</PMID>
  </reference>
  <reference>
    <citation>Klingberg-Allvin M, Cleeve A, Atuhairwe S, Tumwesigye NM, Faxelid E, Byamugisha J, Gemzell-Danielsson K. Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet. 2015 Jun 13;385(9985):2392-8. doi: 10.1016/S0140-6736(14)61935-8. Epub 2015 Mar 27.</citation>
    <PMID>25817472</PMID>
  </reference>
  <reference>
    <citation>Cleeve A, Byamugisha J, Gemzell-Danielsson K, Mbona Tumwesigye N, Atuhairwe S, Faxelid E, Klingberg-Allvin M. Women's Acceptability of Misoprostol Treatment for Incomplete Abortion by Midwives and Physicians - Secondary Outcome Analysis from a Randomized Controlled Equivalence Trial at District Level in Uganda. PLoS One. 2016 Feb 12;11(2):e0149172. doi: 10.1371/journal.pone.0149172. eCollection 2016.</citation>
    <PMID>26872219</PMID>
  </reference>
  <reference>
    <citation>Moran M, Ortega J, Hodoglugil NN. Osur et al.'s Implementation of misoprostol for postabortion care in Kenya and Uganda: a qualitative evaluation. Glob Health Action. 2012 Jul 18;6:21786. doi: 10.3402/gha.v6i0.21786.</citation>
    <PMID>23870184</PMID>
  </reference>
  <reference>
    <citation>Pongsatha S, Tongsong T. Randomized controlled trial comparing efficacy between a vaginal misoprostol loading and non-loading dose regimen for second-trimester pregnancy termination. J Obstet Gynaecol Res. 2014 Jan;40(1):155-60. doi: 10.1111/jog.12147. Epub 2013 Sep 5.</citation>
    <PMID>24033985</PMID>
  </reference>
  <reference>
    <citation>Dawson AJ, Buchan J, Duffield C, Homer CS, Wijewardena K. Task shifting and sharing in maternal and reproductive health in low-income countries: a narrative synthesis of current evidence. Health Policy Plan. 2014 May;29(3):396-408. doi: 10.1093/heapol/czt026. Epub 2013 May 8. Review.</citation>
    <PMID>23656700</PMID>
  </reference>
  <reference>
    <citation>Nabudere H, Asiimwe D, Mijumbi R. Task shifting in maternal and child health care: an evidence brief for Uganda. Int J Technol Assess Health Care. 2011 Apr;27(2):173-9. doi: 10.1017/S0266462311000055. Epub 2011 Mar 30.</citation>
    <PMID>21450128</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>August 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post abortion care</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Second trimester</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Incomplete</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

